Tumour bed boost radiotherapy for women after breast conserving surgery
References
Additional references
Bartelink H, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, et al. Impact of a higher radiation dose on local control and survival in breast‐conserving therapy of early breast cancer: 10‐year results of the randomized boost versus no boost EORTC 22881‐10882 trial. Journal of Clinical Oncology 2007;25(22):3259‐65.
Bartelink H, Maignon P, Poortmans P, Weltens C, Fourquet A, Jager J, et al. on behalf of the European Organisation for Research and Treatment of Cancer Radiation Oncology and Breast Cancer Groups. Whole‐breast irradiation with or without a boost for patients treated with breast‐conserving surgery for early breast cancer: 20‐year follow‐up of a randomised phase 3 trial. Lancet Oncology 2015;16(1):47‐56.
Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, et al. Effect of radiotherapy after breast‐conserving surgery on 10‐year recurrence and 15‐year breast cancer death: meta‐analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet 2011;378(9804):1707‐16.
DerSimonian R, Laird N. Meta‐analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177‐88.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15‐year survival: an overview of the randomized trials. Lancet 2005;365:1687‐717.
EORTC Quality of Life Department. European Organisation for Research and Treatment of Cancer Quality of Life questionnaire ‐ Core 30. http://www.eortc.be/qol/files/SCManualLG‐C30.pdf 1997 (accessed 2 December 2015).
Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty‐year follow‐up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. New England Journal of Medicine 2002;347(16):1233‐41.
Fowler JF. The linear‐quadratic formula and progress in fractionated radiotherapy. British Journal of Radiology 1989;62(740):679‐94.
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.1, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2014. Available from: http://globocan.iarc.fr (accessed 18 May 2015).
Harris JR, Levene MB, Svensson G, Hellman S. Analysis of cosmetic results following primary radiation therapy for stages I and II carcinoma of the breast. International Journal of Radiation Oncology, Biology, Physics 1979;5(2):257‐61.
Hennequin C, Dubray B. Alpha/beta ratio revisited in the era of hypofractionation. Cancer Radiothérapie 2013;17(5‐6):344‐8.
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Holland R, Veling SH, Mravunac M, Hendriks JH. Histologic multifocality of Tis, T1‐T2 breast carcinomas: implication for clinical trials of breast‐conserving surgery. Cancer 1985;56(5):979‐90.
Kellerer AM, Rossi HH. The theory of dual radiation action. Current Topics in Radiation Research 1972;8:85‐158.
Kuerer HM, Julian TB, Strom EA, Lyerly HK, Giuliano AE, Mamounas EP, et al. Accelerated partial breast irradiation after conservative surgery for breast cancer. Annals of Surgery 2004;239(3):338‐51.
Litière S, Werutsky G, Fentiman IS, Rutgers E, Christiaens MR, Van Limbergen E, et al. Breast conserving therapy versus mastectomy for stage I‐II breast cancer: 20 year follow‐up of the EORTC 10801 phase 3 randomised trial. Lancet Oncology 2012;13(4):412‐19.
Malvezzi M, Bertuccio P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2013. Annals of Oncology 2013;24(3):792‐800.
Gradishan WJ, Anderson BO on behalf of the NCCN Breast Cancer Panel Members. National Comprehense Cancer Network Guidelines Breast Cancer. www.nccn.org version 1. 2016 2015 (accessed 2 December 2015).
National Cancer Institute. Common Terminology Criteria for Adverse Events. http://evs.nci.nih.gov/ftp1/CTCAE/About.html 2009 (accessed 2 December 2015).
Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta‐analyses of the publised literature for survival endpoints. Statistics in Medicine 1998;17(24):2815‐34.
The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Sanghani M, Truong PT, Raad RA, Niemierko A, Lesperance M, Olivotto IA, et al. Validation of a web‐based predictive nomogram for ipsilateral breast tumor recurrence after breast conserving therapy. Journal of Clinical Oncology 2010;28(5):718‐22.
Senkus E, Kyriakides S, Ohno S, Penault‐Llorca F, Poortmans P, Rutgers E, et al. on behalf of the ESMO Guidelines Working Group. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow‐up. Annals of Oncology 2015;26(Supplement 5):v8‐v30.
The START Trialists' Group. The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. Lancet Oncology 2008;9(4):331‐41.
Vaidya JS, Joseph DJ, Tobias JS, Bulsara M, Wenz F, Saunders C, et al. Targeted intraoperative radiotherapy versus whole breast radiotherapy for breast cancer (TARGIT‐A trial): an international, prospective, randomised, non‐inferiority phase 3 trial. Lancet 2010;376(9735):91‐102.
van Werkhoven E, Hart G, Tinteren Hv, Elkhuizen P, Collette L, Poortmans P, et al. Nomogram to predict ipsilateral breast relapse based on pathology review from the EORTC 22881‐10882 boost versus no boost trial. Radiotherapy and Oncology 2011;100(1):101‐7.
Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Progress in Cardiovascular Disease 1985;27(5):335‐71.
